← FDA DRUG APPROVALS
FDA ANDA · ANDA201615
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE
Sponsor: CHARTWELL RX
APPLICATION
ANDA201615
TYPE
ANDA
ORIGINAL APPROVAL
2013-01-14
LATEST ACTION
2019-09-30
ROUTE
TOPICAL
DOSAGE FORM
OINTMENT
MARKETING STATUS
Discontinued
Products
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATEDiscontinued
BETAMETHASONE DIPROPIONATE 0.064%, CALCIPOTRIENE 0.005% · OINTMENT · TOPICAL
Approval history
2019-09-30Labeling · Supplement 9 · standardAP
2015-10-14Labeling · Supplement 3 · standardAP
2015-10-14Labeling · Supplement 6 · standardAP
2015-10-14Labeling · Supplement 4 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.